

Stockholm April 18, 2011

Change in the nomination committee's proposal regarding board members

The nomination committee of Swedish Orphan Biovitrum (Sobi) has decided to propose Helena Saxon for election as a new member of the Board of Directors instead of Hans Glemstedt who, following changes within Investor, has decided not to stand for re-election.

Helena Saxon serves as Investment Manager at Investor AB. She has previously served as CFO at PR firm Hallvarsson & Halvarsson and at Synchron International. Helena was born in 1970 and has a M.Sc. in Business and Economics from Stockholm School of Economics.

As announced in connection with the publication of the notice to attend the Annual General Meeting, the nomination committee proposes the re-election of board members Adine Grate Axén, Bo Jesper Hansen, Lennart Johansson, Hans Wigzell and the election of Hans GCP Schikan as a new board member, and that Bo Jesper Hansen be appointed Chairman of the Board of Directors. Wenche Rolfsen and Michael Steinmetz have declined re-election.

The nomination committee consists of Petra Hedengran, Chairman (Investor AB), Roger Johanson (Skandia Liv), Åsa Nisell (Swedbank Robur Fonder) and Chairman of the Board of Directors of Sobi, Bo Jesper Hansen.

The Annual General Meeting will be held at 4 p.m. on April 28, 2011 in the Wallenberg Auditorium at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.

For more information, please contact:

Åsa Stenqvist, Head of Communications and Investor Relations
Phone: +46 8 697 21 88

About Swedish Orphan Biovitrum (Sobi)

Sobi is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer supportive care and inherited metabolic disorders. In 2010 Sobi had revenues of about SEK 1.9 B and approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on April 18, 2011 at 11:15 a.m. CET.